DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification
- PMID: 23349018
- DOI: 10.1093/carcin/bgt022
DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification
Abstract
The clinical and functional significance of RNA-interference machinery in lung cancer is poorly understood. Besides, microRNAs (miRNA) have the potential to serve both as biomarkers and therapeutic agents, by personalizing diagnosis and therapy. In this study, we investigated whether the expression levels of DICER1 and DROSHA, components of the RNA-interference machinery, can predict survival, and whether the miRNA expression profiles can differentiate histologic subtypes in non-small cell lung cancer (NSCLC). Levels of DICER1, DROSHA and five different miRNAs were measured in NSCLC specimens (N = 115) by qRT-PCR assay and correlated with clinical outcomes. Low expression of DROSHA was associated with an increased median survival (154.2 versus 39.8 months, P = 0.016). Also, high DROSHA expression was associated with decreased median survival in the following subgroups: adenocarcinoma (P = 0.011), grade III tumors (P = 0.038) and low-stage patients (P = 0.014). In multivariate analyses, we found two independent predictors of reduced disease-specific survival: high DROSHA expression [hazards ratio = 2.24; P = 0.04] and advanced tumor stage (hazards ratio = 1.29, P = 0.02). In general, the overall tumor miRNA expression was downregulated in our cohort compared with normal tissues. Expression levels of hsa-let-7a (P = 0.005) and miR-16 (P = 0.003) miRNA were significantly higher in squamous cell carcinoma than in adenocarcinoma samples. This study supports the value of the expression profiling of the components of the miRNA-processing machinery in the prognosis of NSCLC patients, especially DROSHA expression levels. In addition, differential expression of miRNAs, such as hsa-let-7a and miR-16 may be helpful tools in the histologic subclassification of NSCLC.
Similar articles
-
A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis.Clin Cancer Res. 2011 Nov 1;17(21):6802-11. doi: 10.1158/1078-0432.CCR-11-0419. Epub 2011 Sep 2. Clin Cancer Res. 2011. PMID: 21890451
-
High copy number variation of cancer-related microRNA genes and frequent amplification of DICER1 and DROSHA in lung cancer.Oncotarget. 2015 Sep 15;6(27):23399-416. doi: 10.18632/oncotarget.4351. Oncotarget. 2015. PMID: 26156018 Free PMC article.
-
The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes.BMC Cancer. 2016 Feb 8;16:71. doi: 10.1186/s12885-016-2104-9. BMC Cancer. 2016. PMID: 26858029 Free PMC article.
-
Gene expression profiling for early-stage NSCLC.Am J Clin Oncol. 2015 Feb;38(1):103-7. doi: 10.1097/COC.0b013e31828d95d8. Am J Clin Oncol. 2015. PMID: 23608827 Review.
-
Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer.Clin Chem Lab Med. 2011 Oct;49(10):1591-603. doi: 10.1515/CCLM.2011.661. Epub 2011 Jul 18. Clin Chem Lab Med. 2011. PMID: 21767219 Review.
Cited by
-
miRNA-Based Technologies in Cancer Therapy.J Pers Med. 2023 Nov 9;13(11):1586. doi: 10.3390/jpm13111586. J Pers Med. 2023. PMID: 38003902 Free PMC article. Review.
-
Dysregulation of microRNA biogenesis machinery in cancer.Crit Rev Biochem Mol Biol. 2016 May-Jun;51(3):121-34. doi: 10.3109/10409238.2015.1117054. Epub 2015 Dec 1. Crit Rev Biochem Mol Biol. 2016. PMID: 26628006 Free PMC article. Review.
-
Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas.Cell Oncol (Dordr). 2015 Aug;38(4):307-17. doi: 10.1007/s13402-015-0231-y. Epub 2015 Jul 31. Cell Oncol (Dordr). 2015. PMID: 26227789
-
Mirtronic miR-4646-5p promotes gastric cancer metastasis by regulating ABHD16A and metabolite lysophosphatidylserines.Cell Death Differ. 2021 Sep;28(9):2708-2727. doi: 10.1038/s41418-021-00779-y. Epub 2021 Apr 19. Cell Death Differ. 2021. PMID: 33875796 Free PMC article.
-
Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer.Oncotarget. 2017 Oct 11;8(55):94980-94996. doi: 10.18632/oncotarget.21739. eCollection 2017 Nov 7. Oncotarget. 2017. PMID: 29212284 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical